Company Yield10 Bioscience, Inc.

Equities

YTEN

US98585K8541

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for Yield10 Bioscience, Inc.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 03:46:06 2024-05-22 pm EDT			5-day change	1st Jan Change
2.29 ^USD	+9.05%		-20.49%	-60.13%

May. 20	Yield10 Bioscience, Inc.(OTCPK:YTEN) dropped from S&P TMI Index	CI
May. 15	Earnings Flash (YTEN) YIELD10 BIOSCIENCE Posts Q1 Revenue $300,000	MT

Yield10 Bioscience, Inc. is an agricultural bioscience company that is leveraging advanced genetics to develop the oilseed Camelina sativa (Camelina) as a platform crop for large-scale production of sustainable seed products. These seed products include feedstock oils for renewable diesel and sustainable aviation biofuels; omega-3 (EPA and DHA+EPA) oils for pharmaceutical, nutraceutical and aquafeed applications; and PHA bioplastics for use as biodegradable bioplastics. The Company is pursuing Camelina seed oil products for two market opportunities and value chains. The first product is seed oil produced by Camelina, which is genetically engineered to enable production of high levels of the omega-3 fatty acids eicosapentanoic acid (EPA) and docosahexanoic acid (DHA). The second product is Camelina seed oil for use as a low-carbon intensity feedstock oil for biofuels, including biodiesel, renewable diesel (RD) and sustainable aviation fuel (SAF).

Number of employees: 29

USD in Million	2022	Weight	2023	Weight	Delta
Specialty Oils and Niche Crops 100.0 %	0	100.0 %	0	100.0 %	-86.67%

USD in Million	2022	Weight	2023	Weight	Delta
United States 100.0 %	0	100.0 %	0	100.0 %	-86.67%

Managers	Title	Age	Since
Oliver Peoples FOU	Founder	66	92-05-31
Charles Haaser DFI	Director of Finance/CFO	68	07-12-31
Kristi Snell CTO	Chief Tech/Sci/R&D Officer	56	96-12-31
Lynne Brum IRC	Investor Relations Contact	60	11-10-31

Members of the board	Title	Age	Since
Robert van Nostrand CHM	Chairman	67	06-09-30
Richard Hamilton BRD	Director/Board Member	61	17-03-01
Oliver Peoples FOU	Founder	66	92-05-31
Anthony Sinskey FOU	Founder	83	92-05-31
Sherri Brown BRD	Director/Board Member	63	20-02-10
Willie Loh BRD	Director/Board Member	69	22-10-03

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	642,546	561,641 ( 87.41 %)	0	87.41 %

Name	Equities	%	Valuation
Jack Schuler 10.39 %	1,600,976	10.39 %	382 633 $
Armistice Capital LLC 6.011 %	925,860	6.011 %	221 281 $
Cannell & Spears LLC 1.611 %	248,113	1.611 %	59 299 $
Cannell & Co. 1.611 %	248,113	1.611 %	59 299 $
Charles Haaser 0.9146 %	140,861	0.9146 %	33 666 $
G1 Execution Services LLC 0.5089 %	78,385	0.5089 %	18 734 $
Oliver Peoples 0.4816 %	74,181	0.4816 %	17 729 $
Richard Hamilton 0.4714 %	72,598	0.4714 %	17 351 $
Anthony Sinskey 0.4173 %	64,274	0.4173 %	15 361 $
Geode Capital Management LLC 0.4058 %	62,497	0.4058 %	14 937 $

Yield10 Bioscience, Inc.

19 Presidential Way

01801-1184, Woburn

+(617) 583-1700

http://www.yield10bio.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

2.29 USD

Average target price

12 USD

Spread / Average Target

+424.02%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
YIELD10 BIOSCIENCE, INC.	-60.13%	1.47M
MODERNA, INC.	+64.23%	62.59B
IQVIA HOLDINGS INC.	-2.31%	41.18B
LONZA GROUP AG	+45.49%	40.29B
CELLTRION, INC.	-8.29%	27.9B
ICON PUBLIC LIMITED COMPANY	+11.97%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.16%	19.09B
BIO-TECHNE CORPORATION	+7.54%	13.08B
MEDPACE HOLDINGS, INC.	+27.17%	12.05B
UNITED THERAPEUTICS CORPORATION	+25.72%	12.26B

Other Biotechnology & Medical Research